<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33044808</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1554-8937</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>20</Day></PubDate></JournalIssue><Title>ACS chemical biology</Title><ISOAbbreviation>ACS Chem Biol</ISOAbbreviation></Journal><ArticleTitle>An Allosteric Modulator of RNA Binding Targeting the N-Terminal Domain of TDP-43 Yields Neuroprotective Properties.</ArticleTitle><Pagination><StartPage>2854</StartPage><EndPage>2859</EndPage><MedlinePgn>2854-2859</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acschembio.0c00494</ELocationID><Abstract><AbstractText>In this study, we targeted the N-terminal domain (NTD) of transactive response (TAR) DNA binding protein (TDP-43), which is implicated in several neurodegenerative diseases. <i>In silico</i> docking of 50K compounds to the NTD domain of TDP-43 identified a small molecule (nTRD22) that is bound to the N-terminal domain. Interestingly, nTRD22 caused allosteric modulation of the RNA binding domain (RRM) of TDP-43, resulting in decreased binding to RNA <i>in vitro</i>. Moreover, incubation of primary motor neurons with nTRD22 induced a reduction of TDP-43 protein levels, similar to TDP-43 RNA binding-deficient mutants and supporting a disruption of TDP-43 binding to RNA. Finally, nTRD22 mitigated motor impairment in a <i>Drosophila</i> model of amyotrophic lateral sclerosis. Our findings provide an exciting way of allosteric modulation of the RNA-binding region of TDP-43 through the N-terminal domain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mollasalehi</LastName><ForeName>Niloufar</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8777-8090</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona 85724, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Innovation in Brain Science, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721-0041, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francois-Moutal</LastName><ForeName>Liberty</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona 85724, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Innovation in Brain Science, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>David D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona 85724, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Innovation in Brain Science, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tello</LastName><ForeName>Judith A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona 85724, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Innovation in Brain Science, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Haley</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona 85724, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Innovation in Brain Science, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahoney</LastName><ForeName>Brendan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, University of California, Los Angeles (UCLA), Los Angeles, California 90095, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Jacob M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona 85724, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Innovation in Brain Science, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Arizona Center for Drug Discovery, College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacology and Toxicology Department, College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xingli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan Health System, Ann Arbor, Michigan 48109, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miranda</LastName><ForeName>Victor G</ForeName><Initials>VG</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona 85724, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Innovation in Brain Science, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gokhale</LastName><ForeName>Vijay</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-2807-4741</Identifier><AffiliationInfo><Affiliation>Bio5 Institute, University of Arizona, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-6043-0860</Identifier><AffiliationInfo><Affiliation>Arizona Center for Drug Discovery, College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacology and Toxicology Department, College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barmada</LastName><ForeName>Sami J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan Health System, Ann Arbor, Michigan 48109, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanna</LastName><ForeName>May</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9989-6374</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona 85724, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Innovation in Brain Science, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG053760</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097542</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016340</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008804</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG063409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS113943</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Chem Biol</MedlineTA><NlmUniqueID>101282906</NlmUniqueID><ISSNLinking>1554-8929</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>12</Day><Hour>17</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33044808</ArticleId><ArticleId IdType="mid">NIHMS1746712</ArticleId><ArticleId IdType="pmc">PMC8548910</ArticleId><ArticleId IdType="doi">10.1021/acschembio.0c00494</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lagier-Tourenne C, Polymenidou M, and Cleveland DW (2010) TDP-43 and FUS/TLS: Emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet 19, R46&#x2013;R64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A, and Buratti E (2016) Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. J. Neurochem 138, 95&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">27015757</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinarbasi ES, Ca&#x11f;atay T, Fung HYJ, Li YC, Chook YM, and Thomas PJ (2018) Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization. Sci. Rep 8, 7083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935693</ArticleId><ArticleId IdType="pubmed">29728608</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, and Lee VMY (2008) Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem 283, 13302&#x2013;13309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL, Zupunski V, Troakes C, Kathe C, Fratta P, Howell M, Gallo JM, Hortob&#xe1;gyi T, Shaw CE, and Rogelj B (2010) Nuclear import impairment causes cytoplasmic transactivation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain 133, 1763&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472655</ArticleId></ArticleIdList></Reference><Reference><Citation>Archbold HC, Jackson KL, Arora A, Weskamp K, Tank EMH, Li X, Miguez R, Dayton RD, Tamir S, Klein RL, and Barmada SJ (2018) TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Sci. Rep 8, 4606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5854632</ArticleId><ArticleId IdType="pubmed">29545601</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Wang L, Lu J, Siedlak SL, Fujioka H, Liang J, Jiang S, Ma X, Jiang Z, Da Rocha EL, Sheng M, Choi H, Lerou PH, Li H, and Wang X (2016) The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat. Med 22, 869&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4974139</ArticleId><ArticleId IdType="pubmed">27348499</ArticleId></ArticleIdList></Reference><Reference><Citation>Afroz T, Hock EM, Ernst P, Foglieni C, Jambeau M, Gilhespy LAB, Laferriere F, Maniecka Z, Pl&#xfc;ckthun A, Mittl P, Paganetti P, Allain FHT, and Polymenidou M (2017) Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat. Commun 8, 45 DOI: 10.1038/s41467-017-00062-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00062-0</ArticleId><ArticleId IdType="pmc">PMC5491494</ArticleId><ArticleId IdType="pubmed">28663553</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang LL, Xue W, Hong JY, Zhang JT, Li MJ, Yu SN, He JH, and Hu HY (2017) The N-terminal dimerization is required for TDP-43 splicing activity. Sci. Rep 7, 6196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5522446</ArticleId><ArticleId IdType="pubmed">28733604</ArticleId></ArticleIdList></Reference><Reference><Citation>Mompe&#xe1;n M, Romano V, Pantoja-Uceda D, Stuani C, Baralle FE, Buratti E, and Laurents DV (2017) Point mutations in the N-terminal domain of transactive response DNA-binding protein 43 kDa (TDP-43) compromise its stability, dimerization, and functions. J. Biol. Chem 292, 11992&#x2013;12006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5512090</ArticleId><ArticleId IdType="pubmed">28566288</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A, Conicella AE, Schmidt HB, Martin EW, Rhoads SN, Reeb AN, Nourse A, Ramirez Montero D, Ryan VH, Rohatgi R, Shewmaker F, Naik MT, Mittag T, Ayala YM, and Fawzi NL (2018) A single N-terminal phosphomimic disrupts TDP-43 polymerization, phase separation, and RNA splicing. EMBO J. 37, No. e97452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5830921</ArticleId><ArticleId IdType="pubmed">29438978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mompe&#xe1;n M, Romano V, Pantoja-Uceda D, Stuani C, Baralle FE, Buratti E, and Laurents DV (2016) The TDP-43 N-terminal domain structure at high resolution. FEBS J. 283, 1242&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pubmed">26756435</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin H, Lim LZ, Wei Y, and Song J (2014) TDP-43 N terminus encodes a novel ubiquitin-like fold and its unfolded form in equilibrium that can be shifted by binding to ssDNA. Proc. Natl. Acad. Sci. U. S. A 111, 18619&#x2013;18624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4284588</ArticleId><ArticleId IdType="pubmed">25503365</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C. ke, Wu TH, Wu CY, Chiang M.-h., Toh EKW, Hsu YC, Lin KF, Liao Y.-h., Huang T.-h., and Huang JJ-T (2012) The N-terminus of TDP-43 promotes its oligomerization and enhances DNA binding affinity. Biochem. Biophys. Res. Commun 425, 219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">22835933</ArticleId></ArticleIdList></Reference><Reference><Citation>Fran&#xe7;ois-Moutal L, Felemban R, Scott DD, Sayegh MR, Miranda VG, Perez-Miller S, Khanna R, Gokhale V, Zarnescu DC, and Khanna M (2019) Small Molecule Targeting TDP-43&#x2019;s RNA Recognition Motifs Reduces Locomotor Defects in a Drosophila Model of Amyotrophic Lateral Sclerosis (ALS). ACS Chem. Biol 14, 2006&#x2013;2013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6911355</ArticleId><ArticleId IdType="pubmed">31241884</ArticleId></ArticleIdList></Reference><Reference><Citation>Lionta E, Spyrou G, Vassilatis D, and Cournia Z (2014) Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances. Curr. Top. Med. Chem 14, 1923&#x2013;1938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4443793</ArticleId><ArticleId IdType="pubmed">25262799</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukavsky PJ, Daujotyte D, Tollervey JR, Ule J, Stuani C, Buratti E, Baralle FE, Damberger FF, and Allain FHT (2013) Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. Nat. Struct. Mol. Biol 20, 1443&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pubmed">24240615</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo PH, Chiang CH, Wang YT, Doudeva LG, and Yuan HS (2014) The crystal structure of TDP-43 RRM1-DNA complex reveals the specific recognition for UG- and TG-rich nucleic acids. Nucleic Acids Res. 42, 4712&#x2013;4722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3985631</ArticleId><ArticleId IdType="pubmed">24464995</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores BN, Li X, Malik AM, Martinez J, Beg AA, and Barmada SJ (2019) An Intramolecular Salt Bridge Linking TDP43 RNA Binding, Protein Stability, and TDP43-Dependent Neurodegeneration. Cell Rep. 27, 1133&#x2013;1150.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6499398</ArticleId><ArticleId IdType="pubmed">31018129</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp K, Safren N, Miguez R, and Barmada S (2019) Monitoring neuronal survival via longitudinal fluorescence microscopy. J. Visualized Exp 2019, DOI: 10.3791/59036.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/59036</ArticleId><ArticleId IdType="pmc">PMC6594158</ArticleId><ArticleId IdType="pubmed">30735193</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Ray P, Rao EJ, Shi C, Guo W, Chen X, Woodruff EA, Fushimi K, and Wu JY (2010) A Drosophila model for TDP-43 proteinopathy. Proc. Natl. Acad. Sci. U. S. A 107, 3169&#x2013;3174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840283</ArticleId><ArticleId IdType="pubmed">20133767</ArticleId></ArticleIdList></Reference><Reference><Citation>Madabattula ST, Strautman JC, Bysice AM, O&#x2019;Sullivan JA, Androschuk A, Rosenfelt C, Doucet K, Rouleau G, and Bolduc F (2015) Quantitative analysis of climbing defects in a drosophila model of neurodegenerative disorders. J. Visualized Exp 2015, DOI: 10.3791/52741.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/52741</ArticleId><ArticleId IdType="pmc">PMC4544889</ArticleId><ArticleId IdType="pubmed">26132637</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y, Lim L, Wang L, and Song J (2016) Inter-domain interactions of TDP-43 as decoded by NMR. Biochem. Biophys. Res. Commun 473, 614&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">27040765</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>